Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hemispherx Biopharma has announced that the arbitration proceeding between the company and Laboratorios del Dr Esteve has been settled and is being dismissed by mutual agreement of the parties.
Subscribe to our email newsletter
Under the terms of the settlement the March 2002 agreement is terminated, Hemispherx regains all licensing rights to Ampligen in Spain, Portugal and Andorra, and Hemispherx and Esteve waive all claims for damages.
In March 2002 Hemispherx entered into an agreement with Laboratorios del Dr Esteve (Esteve) for the sale and distribution of Ampligen in the treatment of patients with chronic fatigue syndrome in Spain, Portugal and Andorra.